Comparision of injection nalbuphine as an adjuvant to injection bupivacaine for pain during post operative period
Not Applicable
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2023/06/053700
- Lead Sponsor
- Datta Meghe Institute of Higher Education and Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients undergoing urological surgeries,duration 1-3 hours.ASA I and II, MPC I and II
Exclusion Criteria
Lack of valid consent,ASA grade III and IV, patient with neurological disorder,bleeding disorder,patients on anticoagulants,infection at block site
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie nalbuphine's opioid receptor modulation in intrathecal bupivacaine analgesia?
How does nalbuphine compare to fentanyl or morphine as an intrathecal adjuvant in urological surgeries?
Are genetic polymorphisms in opioid receptors predictive of nalbuphine-enhanced postoperative analgesia?
What adverse events are associated with nalbuphine-bupivacaine combinations in spinal anesthesia?
What alternative intrathecal adjuvants (e.g., clonidine, dexamethasone) synergize with bupivacaine for urological procedures?